Por Dave Schwab
\nUC San Diego is seeking men and women ages 45 to 80 suffering from Parkinson\u2019s Disease to participate in a research study evaluating the impact of the drug Azilect\u2019s potential for improving cognitive impairment caused by the condition.
\nSponsored by Teva Pharmaceuticals, the clinical trial will not only further the understanding of Parkinson\u2019s disease and a potential treatment but will also provide participants with: \u2022 Clinical trial participation at no cost \u2022 Study-related care at a health care facility, and \u2022 Study-related health care monitoring The recruitment period for the drug trial will continue through March. La Jolla is one of 44 participating sites nationwide. The UCSD Neuroscience, Movement Disorder Center\u2019s Irene Litvan, M.D., director of its Movement Disorders Program, is seeking volunteers in the LaJolla\/San Diego county area to participate in a Parkinson\u2019s disease (PD) clinical research study evaluating the effects of the investigational use of Azilect, rasagiline tablets.
\n“The study is for persons who\u2019ve had some complaints of memory difficulty and difficulty with multitasking,” said Litvan. “The study is for the use of a medication, Azilect, for the purpose of seeing whether it can improve cognitive function in this patient population.”
\nNervous tremors and stiffness are classical symptoms of Parkinson\u2019s Disease. It is hoped, through the Azilect clinical study, that research will shed light on brain function and nerve pathways and how that affects cognition and motor skills.
\nLitvan said subjects chosen for the Parkinson\u2019s study will be administered either a dose of Azilect or a placebo for a month.
\nFor more information call the national Parkinson\u2019s Support Solutions (PSS) at 866-880-8582.<\/p>","protected":false},"excerpt":{"rendered":"
By Dave Schwab UC San Diego is seeking men and women ages 45 to 80 suffering from Parkinson\u2019s Disease to participate in a research study evaluating the impact of the drug Azilect\u2019s potential for improving cognitive impairment caused by the condition. Sponsored by Teva Pharmaceuticals, the clinical trial will not only further the understanding of […]<\/p>","protected":false},"author":840,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_seopress_robots_primary_cat":"11560","_seopress_titles_title":"UC San Diego hosting Parkinsons drug study","_seopress_titles_desc":"","_seopress_robots_index":"","jnews-multi-image_gallery":[],"jnews_single_post":[],"jnews_primary_category":[],"jnews_social_meta":[],"jnews_override_counter":[],"footnotes":""},"categories":[11560,11551,11593],"tags":[],"class_list":["post-303294","post","type-post","status-publish","format-standard","hentry","category-la-jolla-village-news","category-news","category-no-images"],"_links":{"self":[{"href":"https:\/\/test.sdnews.com\/es\/wp-json\/wp\/v2\/posts\/303294","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/test.sdnews.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/test.sdnews.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/test.sdnews.com\/es\/wp-json\/wp\/v2\/users\/840"}],"replies":[{"embeddable":true,"href":"https:\/\/test.sdnews.com\/es\/wp-json\/wp\/v2\/comments?post=303294"}],"version-history":[{"count":0,"href":"https:\/\/test.sdnews.com\/es\/wp-json\/wp\/v2\/posts\/303294\/revisions"}],"wp:attachment":[{"href":"https:\/\/test.sdnews.com\/es\/wp-json\/wp\/v2\/media?parent=303294"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/test.sdnews.com\/es\/wp-json\/wp\/v2\/categories?post=303294"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/test.sdnews.com\/es\/wp-json\/wp\/v2\/tags?post=303294"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}